ICT 2022 | MAASTRICHT, THE NETHERLANDS
19th September 2022 | Poster Viewing I (PV01) Session
P11-12: Human liver patient-derived HUB Organoids® is a promising tool to study drug-induced liver injury and drug metabolism for improved preclinical toxicology assessment
Alessandra Merenda, Merel Derksen, Stephanie Kourula, Marjolein Van Heerden, Ewa Frazer-Mendelewska, Ka Wai Lai, Rob G.J. Vries, Sylvia F. Boj, Jan Snoeys, Farzin Pourfarzad
Abstract: Drug toxicology studies are essential for assessing drug safety and represent a pivotal step in the preclinical stages of drug development. However, advances in drug discovery are often hampered by the lack of suitable preclinical models that recapitulate the in vivo physiology of the tissue, its gene expression, and drug metabolism. Thus, there is a compelling need for advanced in vitro preclinical models to address drug toxicity and to predict drug-Induced liver injury (DILI), given that liver toxicity is one of the leading causes drugs do not reach the market.
Stop by poster P11-12 during ICT or book a meeting in advance with the author to discover:
- How to assess hepatotoxicity using differentiated human liver organoids
- That differentiated liver organoids display more mature hepatocyte phenotypes compared to human stem cells- or induced pluripotent stem cells-derived models
- How to measure metabolic activity and susceptibility to hepatotoxic compounds at a large scale
Want to know more? Request an in-person meeting with an expert.